Work

Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e16107

Authors: Kuaile Zhao, Sung-Bae Kim, Ken Kato, Chih-Hung Hsu, Sheng Hu, Feng Wang, Takashi Kojima, Young Saing Kim, Eric Van Cutsem, Jaffer A. Ajani, Liyun Li, Ningning Ding, Aiyang Tao, Lin Shen

Institutions: Fudan University Shanghai Cancer Center, Asan Medical Center, University of Ulsan, National Cancer Center Hospital, National Taiwan University Hospital, Hubei Cancer Hospital, Zhengzhou University, Henan Cancer Hospital, National Cancer Center Hospital East, Gachon University Gil Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, The University of Texas MD Anderson Cancer Center, BeiGene (China), Peking University Cancer Hospital

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281682823

Cites:

Cited by:

Related to: 10